{"title":"Monoclonal Antibody Therapies for Infectious Diseases.","authors":"Arturo Casadevall, Nigel Paneth","doi":"10.1007/82_2024_265","DOIUrl":null,"url":null,"abstract":"<p><p>In contrast to therapy in oncology and immune-related diseases, where dozens of monoclonal antibodies (mAbs) have been introduced, often in transformative fashion, the use of mAbs for infectious diseases is generally underdeveloped, with fewer than a dozen mAbs currently licensed for the treatment of microbial diseases. This situation is paradoxical given that antibodies are major products of the immune system for protecting against infectious diseases. The underdevelopment of mAbs for infectious diseases has several causes including the availability of effective therapy against many microbial diseases, the fact that many pathogenic microbes are antigenically diverse and thus all strains are not covered by a single mAb, and the high expense of mAb therapies. Despite these hurdles the number of mAbs licensed for infectious disease indications is slowly increasing and there are numerous opportunities for the development of mAbs in the prevention and treatment of microbial diseases.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in microbiology and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/82_2024_265","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
In contrast to therapy in oncology and immune-related diseases, where dozens of monoclonal antibodies (mAbs) have been introduced, often in transformative fashion, the use of mAbs for infectious diseases is generally underdeveloped, with fewer than a dozen mAbs currently licensed for the treatment of microbial diseases. This situation is paradoxical given that antibodies are major products of the immune system for protecting against infectious diseases. The underdevelopment of mAbs for infectious diseases has several causes including the availability of effective therapy against many microbial diseases, the fact that many pathogenic microbes are antigenically diverse and thus all strains are not covered by a single mAb, and the high expense of mAb therapies. Despite these hurdles the number of mAbs licensed for infectious disease indications is slowly increasing and there are numerous opportunities for the development of mAbs in the prevention and treatment of microbial diseases.
在肿瘤和免疫相关疾病的治疗方面，已经有数十种单克隆抗体（mAbs）问世，而且往往是以变革性的方式问世，与此形成鲜明对比的是，mAbs 在感染性疾病方面的应用普遍欠发达，目前获得许可用于治疗微生物疾病的 mAbs 不到十种。鉴于抗体是免疫系统抵御传染病的主要产物，这种情况是自相矛盾的。用于治疗传染病的 mAb 开发不足有几个原因，包括许多微生物疾病都有有效的治疗方法，许多病原微生物的抗原多种多样，因此单一 mAb 无法覆盖所有菌株，以及 mAb 疗法的高昂费用。尽管存在这些障碍，获得传染病适应症许可的 mAb 数量仍在缓慢增加，而且 mAb 在预防和治疗微生物疾病方面的发展机会也很多。
期刊介绍：
The review series Current Topics in Microbiology and Immunology provides a synthesis of the latest research findings in the areas of molecular immunology, bacteriology and virology. Each timely volume contains a wealth of information on the featured subject. This review series is designed to provide access to up-to-date, often previously unpublished information.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
